China Biologic Products Holdings Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of China Biologic Products Holdings Inc (CBPO) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: China Biologic Products Holdings Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 504M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
- Peer revenue share: China Biologic Products Holdings Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
CBPO Sales vs. its Competitors, Q4 2019
China Biologic Products Holdings Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the Biotechnology & Pharmaceuticals industry grew revenue 20.7% year over year, combined, vs 7.9% for China Biologic Products Holdings Inc. China Biologic Products Holdings Inc's share of combined industry revenue moved from 1.29% to 1.15%, a loss of 0.14 percentage points.
China Biologic Products Holdings Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| China Biologic Products Holdings Inc | Yes | Yes | No | No |
| Similar Growth & Profitability (8) | 100.00 % (8 of 8) | 75.00 % (6 of 8) | 12.50 % (1 of 8) | 12.50 % (1 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CBPO Stock Performance relative to its Competitors
CBPO Stock Performance relative to Similar Growth & Profitability Competitors
China Biologic Products Holdings Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| China Biologic Products Holdings Inc | Bio Pharmaceutical Products 90.87 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).